Medical Physics Department, Isfahan University of Medical Science, Isfahan, Iran.
Research & Education, Department of Radiation Oncology, Isfahan Milad Hospital, Isfahan, Iran.
J Mol Neurosci. 2023 Aug;73(7-8):587-597. doi: 10.1007/s12031-023-02136-9. Epub 2023 Jul 18.
The aim of this study was to design a predictive radiobiological model of normal brain tissue in low-grade glioma following radiotherapy based on imaging and molecular biomarkers. Fifteen patients with primary brain tumors prospectively participated in this study and underwent radiation therapy. Magnetic resonance imaging (MRI) was obtained from the patients, including T1- and T2-weighted imaging and diffusion tensor imaging (DTI), and a generalized equivalent dose (gEUD) was calculated. The radiobiological model of the normal tissue complication probability (NTCP) was performed using the variables gEUD; axial diffusivity (AD) and radial diffusivity (RD) of the corpus callosum; and serum protein S100B by univariate and multivariate logistic regression XLIIIrd Sir Peter Freyer Memorial Lecture and Surgical Symposium (2018). Changes in AD, RD, and S100B from baseline up to the 6 months after treatment had an increasing trend and were significant in some time points (P-value < 0.05). The model resulting from RD changes in the 6 months after treatment was significantly more predictable of necrosis than other univariate models. The bivariate model combining RD changes in Gy40 dose-volume and gEUD, as well as the trivariate model obtained using gEUD, RD, and S100B, had a higher predictive value among multivariate models at the sixth month of the treatment. Changes in RD diffusion indices and in serum protein S100B value were used in the early-delayed stage as reliable biomarkers for predicting late-delayed damage (necrosis) caused by radiation in the corpus callosum. Current findings could pave the way for intervention therapies to delay the severity of damage to white matter structures, minimize cognitive impairment, and improve the quality of life of patients with low-grade glioma.
本研究旨在设计一种基于影像学和分子生物标志物的低级别胶质瘤放疗后正常脑组织预测性放射生物学模型。15 名原发性脑肿瘤患者前瞻性参与本研究并接受放射治疗。对患者进行磁共振成像(MRI)检查,包括 T1 和 T2 加权成像和弥散张量成像(DTI),并计算广义等效剂量(gEUD)。使用 gEUD;胼胝体的轴向弥散度(AD)和径向弥散度(RD);以及血清蛋白 S100B 等变量,通过单变量和多变量逻辑回归来进行正常组织并发症概率(NTCP)的放射生物学模型分析。XLIIIrd Sir Peter Freyer Memorial Lecture and Surgical Symposium(2018)。治疗后 6 个月内 AD、RD 和 S100B 的变化呈上升趋势,在某些时间点具有统计学意义(P 值<0.05)。治疗后 6 个月 RD 变化的模型比其他单变量模型更能预测坏死。包含 Gy40 剂量-体积和 gEUD 的 RD 变化的双变量模型,以及使用 gEUD、RD 和 S100B 获得的三变量模型,在治疗第 6 个月的多变量模型中具有更高的预测价值。RD 扩散指数和血清蛋白 S100B 值的变化可用于早期迟发性阶段,作为预测胼胝体辐射引起的迟发性损伤(坏死)的可靠生物标志物。目前的研究结果为干预治疗铺平了道路,以延迟白质结构损伤的严重程度,最大限度地减少认知障碍,并提高低级别胶质瘤患者的生活质量。